Evidence map›Paper›PMID 27866654›Full record

ReviewCell2017

CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

Alexis C Komor, Ahmed H Badran, David R Liu

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 479 papers.

0numbers the graph read from it
0cells of the map it votes in
479citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

479 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Fully computational design of PAM-relaxedbioRxiv : the preprint server for biology · 2026
    Article
  19. Article
  20. Reprogramming mRNA localization by targeted RNA-protein interference.bioRxiv : the preprint server for biology · 2026
    Article

419 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Alexis C KomorDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
Ahmed H BadranDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA.
David R LiuDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Harvard University, Cambridge, MA 02138, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA. Electronic address: drliu@fas.harvard.edu.

Funding

Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel TherapeuticsR35GM118062 · NIGMS · HARVARD UNIVERSITY · PI LIU, DAVID R · 2016 to 2025
$6.4M
Expanding the Scope of Protein EvolutionR01GM065400 · NIGMS · HARVARD UNIVERSITY · PI LIU, DAVID R · 2002 to 2010
$2.5M
Continuous Evolution of Proteins with Novel Therapeutic PotentialR01EB022376 · NIBIB · HARVARD UNIVERSITY · PI LIU, DAVID R · 2016 to 2019
$1.8M
Development and validation of a precision genome editing platformF32GM112366 · NIGMS · HARVARD UNIVERSITY · PI KOMOR, ALEXIS C. · 2015 to 2017
$122k
Howard Hughes Medical InstituteNIBIB NIH HHS R01 EB022376NIGMS NIH HHS F32 GM112366NIGMS NIH HHS R01 GM065400NIGMS NIH HHS R35 GM118062
6 · The paper itself

Abstract

The CRISPR-Cas9 RNA-guided DNA endonuclease has contributed to an explosion of advances in the life sciences that have grown from the ability to edit genomes within living cells. In this Review, we summarize CRISPR-based technologies that enable mammalian genome editing and their various applications. We describe recent developments that extend the generality, DNA specificity, product selectivity, and fundamental capabilities of natural CRISPR systems, and we highlight some of the remarkable advancements in basic research, biotechnology, and therapeutics science that these developments have facilitated.

Indexed as

AnimalsCells, CulturedCRISPR-Cas SystemsDiseaseDisease Models, AnimalEpigenomicsGene EditingGenetic TherapyHumans

Identifiers

PMID27866654
PMCPMC5235943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.